Drugs in Dev. Infections and Infectious Diseases
IND Enabling
France 
Lead Product(s) : MRT5500
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Sanofi
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Preclinical evaluation of MRT5500, importantly, demonstrated a favorable immune response profile against SARS-CoV-2. These data support the selection of MRT5500 for clinical development.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
October 15, 2020
Lead Product(s) : MRT5500
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Sanofi
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Phage therapy intravenous infusion are harmless to human organisms and specifically eradicate bacteria in an ultra-targeted way to fight microbial infections.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 24, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
